The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Open accessAbstract
BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic melanoma. METHODS: We assigned, in a 1:1:1 ratio, 945 previously untreated patients with unresectable stage III or IV melanoma to nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone. Progression-free survival and overall survival were coprimary end points. Results regarding progression-free survival are presented here. RESULTS: The median progression-free survival was 11.5 months (95% confidence interval [CI], 8.9 to 16.7) with nivolumab plus ipilimumab, as compared with 2.9 months (95% CI, 2.8 to 3.4) with ipilimumab (hazard ratio for death or disease progression, 0.42; 99.5% CI, 0.31 to 0.57; P<0.001), and 6.9 months (95% CI, 4.3 to 9.5) with nivolumab (hazard ratio for the comparison with ipilimumab, 0.57; 99.5% CI, 0.43 to 0.76; P<0.001). In patients with tumors positive for the PD-1 ligand (PD-L1), the median progression-free survival was 14.0 months in the nivolumab-plus-ipilimumab group and in the nivolumab group, but in patients with PD-L1-negative tumors, progression-free survival was longer with the combination therapy than with nivolumab alone (11.2 months [95% CI, 8.0 to not reached] vs. 5.3 months [95% CI, 2.8 to 7.1]). Treatment-related adverse events of grade 3 or 4 occurred in 16.3% of the patients in the nivolumab group, 55.0% of those in the nivolumab-plus-ipilimumab group, and 27.3% of those in the ipilimumab group. CONCLUSIONS: Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipilimumab alone. In patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone. (Funded by Bristol-Myers Squibb; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A direct comparison between the two checkpoint inhibitors in a Phase III clinical trial found better response (44%) and survival rates (6.9 months progression-free survival) among patients treated with the anti-PD-1 antibody nivolumab than among those treated with the anti-CTLA-4 antibody ipilimumab (19% and 2.8 months).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [67]
In the citing paper
“Combined administration of both nivolumab and ipilimumab resulted in even higher response rates (58%) and survival (11.5 months) (67).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [67]
In the citing paper
“Even more patients were affected when treated with a combination of both (55%) (67).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [67]
In the citing paper
“Clinical trials that directly compared different types of immune checkpoint inhibitors and their combination noted that more patients experienced side effects when treated with anti-CTLA-4 (27.3%) compared to anti-PD-1 (16.3%).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [67]
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [67]
In the citing paper
“Severe adverse reactions include severe diarrhea, colitis, increased alanine aminotransferase levels, inflammation pneumonitis, and interstitial nephritis (67, 73, 99).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [67]
In the citing paper
“Multiple clinical trials with combined blockade of CTLA4 and PD-1/PD-L1 demonstrated higher response rates than either monotherapy, in different cancer types including melanoma ( 54, 55 ), hepatocellular carcinoma ( 56 ), renal cell carcinoma (RCC; refs.57, 58 ), NSCLC ( 59 ), malignant pleural mesothelioma ( 60 ), and colorectal cancer (MSI-H/dMMR; ref. 61 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [54]
In the citing paper
“Immune checkpoint blockade therapies have markedly advanced cancer treatment by invigorating antitumor immunity and extending patient survival.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Larkin et al., 2015
In the citing paper
“treatment-limiting toxicity with anti-PD-1 (16%), anti-CTLA-4 (27%), and combination therapies (65%)”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Larkin et al., 2015
In the citing paper
“At the end of the trial, progression-free survival was highest in patients who received the combination therapy, followed by patients treated with nivolumab alone, and was lowest in patients treated with ipilimumab alone (59).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [59]
In the citing paper
“In patients with untreated melanoma, treatment with anti-CTLA-4 led to grade 3 or 4 irAEs in 27.3% of patients and treatment with anti-PD-1 led to such severe irAEs in only 16.3% of patients (59).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [59]
In the citing paper
“Combination treatment of advanced melanoma with both anti-CTLA-4 and anti-PD-1 led to a marked increase in both the incidence and the severity of irAEs, with 55% of those patients exhibiting high-grade irAEs (59).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [59]
In the citing paper
“Although the immune checkpoint inhibitors have success in treating various malignancies, there is still a significant number of patients that can use such therapy only for a limited amount of time, given the occurrence of strong toxic side effects, including gut inflammation, due to the subsequent immune-dysregulation (i.e., autoimmunity) [177].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [177]
In the citing paper
“Therefore, ipilimumab is commonly administrated at a reduced dose [154], which might weaken the efficacy of combination therapy.”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Sznol M, 2014, J Clin Oncol, 52, 15
Cited by
Sorted by citations
Items 501–600 of 1,078
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250
Kansy, B., Concha‐Benavente, F., Srivastava, R. M., Jie, H.-B., Shayan, G., Lei, Y. L., Moskovitz, J. M., Moy, J. D., Li, J., Brandau, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3167 · Cited by 258
Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0193 · Cited by 248
Zhang, Y., Li, N., Suh, H., & Irvine, D. J. (2017) · Nature Communications · doi:10.1038/s41467-017-02251-3 · Cited by 248
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
Rashidian, M., Ingram, J. R., Dougan, M. L., Dongre, A., Whang, K. A., Gall, C. M. L., Cragnolini, J. J., Bierie, B., Gostissa, M., Gorman, J. R., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161950 · Cited by 253
Long, G. V., Atkinson, V. G., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30428-x · Cited by 248
Self-citationCardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247
Diehl, A., Yarchoan, M. M., Hopkins, A., Jaffee, E. M., & Grossman, S. A. (2017) · Oncotarget · doi:10.18632/oncotarget.23217 · Cited by 249
Lin, A. G., Gorbanev, Y. Y., Backer, J. D., Loenhout, J. V., Boxem, W. V., Lemière, F., Cos, P., Dewilde, S., Smits, E., & Bogaerts, A. (2019) · Advanced Science · doi:10.1002/advs.201802062 · Cited by 249
Zimmer, L., Livingstone, E., Hassel, J. C., Fluck, M., Eigentler, T., Loquai, C., Haferkamp, S., Gutzmer, R., Meier, F. E., Mohr, P., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30417-7 · Cited by 251
Self-citationImmunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Ralli, M., Botticelli, A., Visconti, I. C., Angeletti, D., Fiore, M., Marchetti, P., Lambìase, A., VINCENTIIS, M. D., & Greco, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9235638 · Cited by 254
Ascierto, P. A., Mandalà, M., Ferrucci, P. F., Guidoboni, M., Rutkowski, P. L., Ferraresi, V., Arance, A. M., Guida, M., Maiello, E., Gogas, H. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02961 · Cited by 255
Self-citationClinical cancer immunotherapy: Current progress and prospects
Liu, C., Yang, M., Zhang, D., Chen, M., & Zhu, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961805 · Cited by 261
Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246
Khair, D. O., Bax, H. J., Mele, S., Crescioli, S., Pellizzari, G., Khiabany, A., Nakamura, M., Harris, R. J. C., French, E., Hoffmann, R. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00453 · Cited by 252
Ott, P. A., Hodi, F. S., & Buchbinder, E. I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00202 · Cited by 252
Self-citationDecker, W. K., da Silva, R. F., Sanabria, M. H., Angelo, L. S., Guimarães, F., Burt, B. M., Kheradmand, F., & Paust, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00829 · Cited by 254
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
Khan, S., & Gerber, D. E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.012 · Cited by 250
Hoch, T., Schulz, D., Eling, N., Gómez, J. M. M., Levesque, M. P., & Bodenmiller, B. (2022) · Science Immunology · doi:10.1126/sciimmunol.abk1692 · Cited by 253
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244
Teng, F., Meng, X., Kong, L., & Yu, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.014 · Cited by 249
Wang, Y., Abu‐Sbeih, H., Mao, E., Ali, N., Ali, F. S., Qiao, W., Lum, P. J., Raju, G. S., Shuttlesworth, G. A., Stroehlein, J., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0346-6 · Cited by 244
Molecular Markers and Targets in Melanoma
Teixidó, C., Castillo, P., Martínez-Vila, C., Arance, A. M., & Alós, L. (2021) · Cells · doi:10.3390/cells10092320 · Cited by 262
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
Lee, J.-M., Cimino‐Mathews, A., Peer, C. J., Zimmer, A. S., Lipkowitz, S., Annunziata, C. M., Cao, L., Harrell, M. I., Swisher, E. M., Houston, N. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1340 · Cited by 243
Targeted therapies for renal cell carcinoma
Posadas, E. M., Limvorasak, S., & Figlin, R. A. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.82 · Cited by 246
Mechanisms of immune activation and regulation: lessons from melanoma
Kalaora, S., Nagler, A., Wargo, J. A., & Samuels, Y. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00442-9 · Cited by 252
Amaro, A. A., Gangemi, R. M. R., Piaggio, F., Angelini, G., Barisione, G., Ferrini, S., & Pfeffer, U. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9663-3 · Cited by 246
Radiation effects on antitumor immune responses: current perspectives and challenges
Walle, T., Monge, R. M., Cerwenka, A., Ajona, D., Melero, I., & Lecanda, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017742575 · Cited by 250
Wang, E., & Aifantis, I. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.04.011 · Cited by 246
Systemic Therapy for Melanoma: ASCO Guideline Update
Seth, R., Agarwala, S. S., Messersmith, H. J., Alluri, K. C., Ascierto, P. A., Atkins, M. B., Bollin, K. B., Chacon, M. R., Davis, N. B., Faries, M. B., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01136 · Cited by 251
Self-citationWang, Z., Zhao, J., Wang, G., Zhang, F., Zhang, Z., Zhang, F., Zhang, Y., Dong, H., Zhao, X., Duan, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1814 · Cited by 241
The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
Cai, J., Wang, D., Zhang, G., & Guo, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s221340 · Cited by 251
Qu, S., Worlikar, T., Felsted, A. E., Ganguly, A., Beems, M. V., Hubbard, R. T., Pepple, A., Kevelin, A. A., Garavaglia, H., Dib, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000200 · Cited by 244
PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity
Kim, H., Kim, H., Feng, Y., Li, Y., Tamiya, H., Tocci, S., & Ronai, Z. A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz5683 · Cited by 247
Trial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Ahmed, K. A., Stallworth, D. G., Kim, Y., Johnstone, P. A. S., Harrison, L. B., Caudell, J. J., Yu, H., Etame, A. B., Weber, J. S., & Gibney, G. T. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv622 · Cited by 240
Manegold, C., Dingemans, A. C., Gray, J. E., Nakagawa, K., Nicolson, M. C., Peters, S., Reck, M., Wu, Y.-L. L. C., Brustugun, O. T., Crinò, L., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.003 · Cited by 243
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
Lesterhuis, W. J., Bosco, A., Millward, M., SMALL, M. P., Nowak, A. K., & Lake, R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.233 · Cited by 244
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Moreira, A., Loquai, C., Pföhler, C., Kähler, K. C., Knauß, S., Heppt, M. V., Gutzmer, R., Dimitriou, F., Meier, F. E., Mitzel-Rink, H., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.033 · Cited by 242
Self-citationNanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy
Musetti, S., & Huang, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05893 · Cited by 240
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Sullivan, R. J., Hamid, O., Gonzalez, R. C., Infante, J. R., Patel, M. R., Hodi, F. S., Lewis, K. D., Tawbi, H. A., Hernandez, G., Wongchenko, M. J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0474-7 · Cited by 242
Self-citationManagement of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
Weber, J. S., Postow, M. A., Lao, C. D., & Schadendorf, D. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0055 · Cited by 244
Self-citationHallmarks of response to immune checkpoint blockade
Cogdill, A. P., Andrews, M. C., & Wargo, J. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.136 · Cited by 251
Santoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., Giannini, M., Cognigni, P. D., Ferrara, G., & Battelli, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.007 · Cited by 241
Cancer immunotherapy: broadening the scope of targetable tumours
van den Bulk, J., Verdegaal, E. M. E., & de Miranda, N. F. C. C. (2018) · Open Biology · doi:10.1098/rsob.180037 · Cited by 244
Treg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 242
Immune checkpoints in the tumor microenvironment
Toor, S. M., Nair, V. S., Decock, J. V., & Elkord, E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.021 · Cited by 242
Diab, A., Tannir, N. M., Bentebibel, S.-E., Hwu, P., Papadimitrakopoulou, V., Haymaker, C., Kluger, H. M., Gettinger, S. N., Sznol, M., Tykodi, S. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1510 · Cited by 237
Self-citationImmune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Du, W., Yang, M., Turner, A., Xu, C., Ferris, R. L., Huang, J., Kane, L., & Lu, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030645 · Cited by 242
Weinmann, S. C., & Pisetsky, D. S. (2019) · Rheumatology · doi:10.1093/rheumatology/kez308 · Cited by 243
Oh, D. Y., Cham, J., Zhang, L., Fong, G., Kwek, S. S., Klinger, M., Faham, M., & Fong, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2324 · Cited by 236
Francis, D. M., Manspeaker, M. P., Schudel, A., Sestito, L. F., O’Melia, M. J., Kissick, H. T., Pollack, B. P., Waller, E. K., & Thomas, S. N. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay3575 · Cited by 240
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
Ge, Z., Peppelenbosch, M. P., Sprengers, D., & Kwekkeboom, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.699895 · Cited by 243
TIM-3, a promising target for cancer immunotherapy
He, Y., Cao, J., Zhao, C., Li, X., Zhou, C., & Hirsch, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170385 · Cited by 235
Tolcher, A. W., Sznol, M., Hu‐Lieskovan, S., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Gravio, D. D., Huang, B., Gambhire, D., Chen, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1243 · Cited by 240
Self-citationProgrammed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus
Clotman, K., Janssens, K., Specenier, P. M., Weets, I., & Block, C. E. M. D. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00728 · Cited by 237
Clinical development of targeted and immune based anti-cancer therapies
Seebacher, N. A., Stacy, A. E., Porter, G., & Merlot, A. M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1094-2 · Cited by 241
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
Tahir, S. A., Gao, J., Miura, Y., Blando, J. M., Tidwell, R. S. S., Zhao, H., Subudhi, S. K., Tawbi, H. A., Keung, E. Z.-Y., Wargo, J. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908079116 · Cited by 238
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 250
Learning from clinical trials of neoadjuvant checkpoint blockade
Versluis, J. M., Long, G. V., & Blank, C. U. (2020) · Nature Medicine · doi:10.1038/s41591-020-0829-0 · Cited by 234
Self-citationVedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Curry, J. L., Tetzlaff, M. T., Nagarajan, P., Drucker, C. R., Diab, A. K., Hymes, S. R., Duvic, M. A., Hwu, W., Wargo, J. A., Torres-Cabala, C. A., et al. (2016) · Journal of Cutaneous Pathology · doi:10.1111/cup.12858 · Cited by 235
Cruz, E., & Kayser, V. (2019) · Biologics · doi:10.2147/btt.s166310 · Cited by 245
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
Yuan, J. D., Hegde, P. S., Clynes, R., Foukas, P. G., Harari, A., Kleen, T. O., Kvistborg, P., Maccalli, C., Maecker, H. T., Page, D. B., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0107-3 · Cited by 235
Etzerodt, A., Tsalkitzi, K., Maniecki, M. B., Damsky, W., Delfini, M., Baudoin, E., Moulin, M., Bosenberg, M., Graversen, J. H., Auphan‐Anezin, N., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182124 · Cited by 242
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Amaral, T. M. S., Ottaviano, M., Arance, A. M., Blank, C. U., Chiarion‐Sileni, V., Donia, M., Dummer, R., Garbe, C., Gershenwald, J. E., Gogas, H. J., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.11.006 · Cited by 248
Self-citationImmune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Braaten, T. J., Brahmer, J. R., Forde, P. M., Le, D., Lipson, E. J., Naidoo, J., Schollenberger, M., Zheng, L., Bingham, C. O., Shah, A. A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216109 · Cited by 230
Girotti, M. R., Gremel, G., Lee, R. J., Galvani, E., Rothwell, D. G., Virós, A., Mandal, A. K., Lim, K. H. J., Saturno, G., Furney, S. J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1336 · Cited by 235
Selby, M., Engelhardt, J., Johnston, R. J., Lu, L.-S., Han, M., Thudium, K. B., Yao, D., Quigley, M. M., Valle, J., Wang, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161779 · Cited by 236
McArthur, H. L., Diab, A. K., Page, D. B., Yuan, J. D., Solomon, S. B., Sacchini, V., Comstock, C., Durack, J. C., Maybody, M., Sung, J. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0190 · Cited by 230
Self-citationDesigning nanomedicine for immuno-oncology
Jiang, W., Roemeling, C. A. V., Chen, Y., Qie, Y., Liu, X., Chen, J., & Kim, B. Y. S. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0029 · Cited by 230
Targeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 237
Mansurov, A., Ishihara, J., Hosseinchi, P., Potin, L., Marchell, T. M., Ishihara, A., Williford, J., Alpar, A. T., Raczy, M. M., Gray, L. T., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0549-2 · Cited by 230
Patel, R. B., Hernandez, R. T., Carlson, P. M., Grudzinski, J. J., Bates, A. M., Jagodinsky, J. C., Erbe, A. K., Marsh, I. R., Arthur, I. S., Aluicio‐Sarduy, E., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb3631 · Cited by 230
Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes
Kotwal, A., Haddox, C., Block, M., & Kudva, Y. C. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000591 · Cited by 228
Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Foppen, M. H. G., Hoejberg, L., Schmidt, H., van Thienen, J. V., Haanen, J. B. A. G., Tiainen, L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz110 · Cited by 229
Self-citationCombining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
Yan, Y., Kumar, A. B., Finnes, H. D., Markovic, S. N., Park, S. S., Dronca, R. S., & Dong, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01739 · Cited by 231
Rational design of anti-GITR-based combination immunotherapy
Zappasodi, R., Sirard, C. A., Li, Y., Budhu, S., Abu-Akeel, M., Liu, C., Yang, X., Zhong, H., Newman, W., Qi, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0420-8 · Cited by 233
Self-citationSubudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
Singh, P., Toom, S., & Huang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0473-4 · Cited by 226
Long, G. V., Eroglu, Z., Infante, J. R., Patel, S. P., DAUD, A. I., Johnson, D. B., Gonzalez, R. C., Kefford, R. F., Hamid, O., Schuchter, L. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.1025 · Cited by 229
Self-citationChemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity
Karin, N., & Razon, H. (2018) · Cytokine · doi:10.1016/j.cyto.2018.02.012 · Cited by 229
Ben‐Ami, E., Barysauskas, C. M., Solomon, S., Tahlil, K., Malley, R., Hohos, M., Polson, K., Loucks, M., Severgnini, M., Patel, T., et al. (2017) · Cancer · doi:10.1002/cncr.30738 · Cited by 231
Self-citationVillarroel‐Espíndola, F., Yu, X., Datar, I. J., Mani, N. L., Sanmamed, M. F., Velcheti, V., Syrigos, K., Toki, M. I., Zhao, H., Chen, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2542 · Cited by 226
Revisiting Immunotherapy: A Focus on Prostate Cancer
Cha, H.-R., Lee, J. H., & Ponnazhagan, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2948 · Cited by 228
da Silva, I. P., Ahmed, T., Reijers, I. L. M., Weppler, A. M., Warner, A. B., Patrinely, J. R., Serra-Bellver, P., Allayous, C., Mangana, J., Nguyen, K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00097-8 · Cited by 229
Self-citationCampesato, L. F., Barroso‐Sousa, R., Jimenez, L., Corrêa, B., Sabbaga, J., Hoff, P. M., Reis, L. F. L., Galante, P. A. F., & Camargo, A. A. (2015) · Oncotarget · doi:10.18632/oncotarget.5950 · Cited by 224
Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
Joshi, M., Whitelaw, B., Palomar, M. T. P., Wu, Y., & Carroll, P. (2016) · Clinical Endocrinology · doi:10.1111/cen.13063 · Cited by 224
Burugu, S., Asleh, K., & Nielsen, T. O. (2016) · Breast Cancer · doi:10.1007/s12282-016-0698-z · Cited by 234
Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade
Wang, F., Yin, Q., Chen, L., & Davis, M. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712901115 · Cited by 223
Lee, Y., Shin, J. H., Longmire, M. R., Wang, H., Kohrt, H. E. K., Chang, H. Y., & Sunwoo, J. B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2665 · Cited by 225
Rationale for anti-GITR cancer immunotherapy
Knee, D. A., Hewes, B., & Brogdon, J. L. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.028 · Cited by 223
Naing, A., Papadopoulos, K. P., Autio, K. A., Ott, P. A., Patel, M. R., Wong, D. J. L., Falchook, G. S., Pant, S., Whiteside, M., Rasco, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1106 · Cited by 221
Willingham, S. B., Ho, P. Y., Hotson, A. N., Hill, C. M., Piccione, E. C., Hsieh, J. Y., Liu, L., Buggy, J. J., McCaffery, I., & Miller, R. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0056 · Cited by 225
Wu, L., Mao, L., Liu, J., Chen, L., Yu, G., Yang, L., Wu, H., Bu, L., Kulkarni, A. B., Zhang, W., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0725 · Cited by 223
Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
Birzu, C., French, P. J., Caccese, M., Cerretti, G., Idbaïh, A., Zagonel, V., & Lombardi, G. (2020) · Cancers · doi:10.3390/cancers13010047 · Cited by 229
Advancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · 癌症：英文版 · doi:10.1002/cac2.12178 · Cited by 221
Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 229
Metadata
- Authors
- Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., Ferrucci, P. F., Hill, A., Wagstaff, J., Carlino, M. S., Haanen, J. B., Maio, M., Marquez-Rodas, I., McArthur, G. A., Ascierto, P. A., Long, G. V., Callahan, M. K., Postow, M. A., Grossmann, K., Sznol, M., Dreno, B., Bastholt, L., Yang, A., Rollin, L. M., Horak, C., Hodi, F. S., & Wolchok, J. D.
- Affiliations
- University of Siena (IT)
- From the Department of Medical Oncology, Royal Marsden Hospital, London (J.L.), and South West Wales Cancer Institute, Singleton Hospital, Swansea (J.W.) — both in the United Kingdom; Melanoma Oncology Unit, Veneto Region Oncology Research Institute, Padua (V.C.-S.), Oncology of Melanoma Unit, European Institute of Oncology, Milan (P.F.F.), University Hospital of Siena, Siena (M.M.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) — all in Italy; Division of Medical Oncology, University...
- ORCID
- Larkin, James
- Gonzalez, Rene
- Grob, Jean Jacques
- Cowey, C. Lance
- Schadendorf, Dirk
- Dummer, Reinhard
- Smylie, Michael
- Rutkowski, Piotr
- Ferrucci, Pier F.
- Wagstaff, John
- Carlino, Matteo S.
- Haanen, John B.
- Maio, Michele
- McArthur, Grant A.
- Ascierto, Paolo A.
- Long, Georgina V.
- Callahan, Margaret K.
- Postow, Michael A.
- Grossmann, Kenneth
- Sznol, Mario
- Bastholt, Lars
- Hodi, F. Stephen
- Wolchok, Jedd D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-02
- Volume
- 373
- Issue
- 1
- Pages
- 23-34
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5698905
- OpenAlex
- W2166662937
- Semantic Scholar
- f1d33462f43c22bfc0b6d687ce5866eacb6b188e
- Cited by
- 8,157
- References
- 22
- Citations by year
- 2026: 295 · 2025: 388 · 2024: 530 · 2023: 626 · 2022: 689 · 2021: 827 · 2020: 925 · 2019: 867 · 2018: 925 · 2017: 1039 · 2016: 837 · 2015: 190
- FWCI
- 435.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- ab, ipilimumab, metastatic melanoma, PD-1 inhibitors, CTLA-4 inhibitors, immune checkpoint inhibitors, combination immunotherapy, PD-L1 expression, progression-free survival, overall survival, treatment-related adverse events, immune-related adverse events, immune-related pneumonitis, immune-related colitis, immune-related endocrinopathy, immune-related hepatitis
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Disease-Free Survival, Tumor Burden, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
